


Receipt date: 05/22/2009

10541708 - GAU: 1644

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/541,708		ATTY. DOCKET NO.: A0848.70010US00		
				FILING DATE: July 8, 2005		CONFIRMATION NO.: 6032		
				APPLICANT: Karen Silence				
				GROUP ART UNIT: 1644		EXAMINER: Michael Edward Szperka		
Sheet	1	of	4					

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		6,228,360	B1	Co et al.	05-08-2001
		7,311,913	B2	Co et al.	12-25-2007
		2005-0192224	A1	Huizinga et al.	09-01-2005
		2005-0136056	A1	Kageyama et al.	06-23-2006
		2006-0286066	A1	Basran	12-21-2006
		2008-0096223	A1	De Groot et al.	04-24-2008

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
			PCT/EP03/06581/		Ablynx N.V.	06-23-2003	
			PCT/EP03/07313 /		Ablynx N.V.	07-08-2003	
			PCT/BE03/00206 /		Ablynx N.V.	12-01-2003	
			PCT/BE03/00191 /		Ablynx N.V.	12-02-2003	
		EP	03447005.4 ✓		Ablynx N.V.	01-10-2003	
		WO	01/002853 /	A2	Roche Diagnostics GMBH	01-11-2001	
		WO	2004/015425 /	A1	UMC Utrecht Holding B.V.	02-19-2004	
		WO	2004/041867 /	A2	Ablynx N.V.	05-21-2004	
		WO	2005/044858 ✓	A1	Ablynx N.V.	05-19-2005	
		WO	2006/074947 /	A2	Ablynx N.V.	07-20-2006	
		WO	2008/049881 /	A3	UMC Utrecht Holding BV	05-02-2008	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		[No Author Listed] The Merck Manual of Diagnosis and Therapy, 17 th Ed. Beers et al, Editors. Merck Research Laboratories, 1999:926-7.	
		[No Author Listed] Von Willebrand disease. www.wikipedia.org. Accessed December 30, 2008.	
		BERNDT et al., The vascular biology of the glycoprotein Ib-IX-V complex. Thromb Haemost. 2001 Jul;86(1):178-88. Review	
		BLANCO et al., Formation and stability of beta-hairpin structures in polypeptides. Curr Opin Struct Biol. 1998 Feb;8(1):107-11. Review.	
		BONNEFOY et al., Shielding the front-strand beta 3 of the von Willebrand factor A1 domain	

EXAMINER: /Michael Szperka/	DATE CONSIDERED: 08/31/2009
------------------------------------	------------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

1568886.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MS/

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICATION NO.: 10/541,708	ATTY. DOCKET NO.: A0848.70010US00
		FILING DATE: July 8, 2005	CONFIRMATION NO.: 6032
		APPLICANT: Karen Silence et al.	
		GROUP ART UNIT: 1644	EXAMINER: Michael Edward Szperka
Sheet	2	of	4

	inhibits its binding to platelet glycoprotein Ibalpha. Blood. 2003 Feb 15;101(4):1375-83. Epub 2002 Oct 10.	
	CELIKEL et al., von Willebrand factor conformation and adhesive function is modulated by an internalized water molecule. Nat Struct Biol. 2000 Oct;7(10):881-4.	
	CELIKEL et al., Crystal structure of the von Willebrand factor A1 domain in complex with the function blocking NMC-4 Fab. Nat Struct Biol. 1998 Mar;5(3):189-94.	
	CHAND et al., A two-site, monoclonal antibody-based immunoassay for von Willebrand factor—demonstration that vWF function resides in a conformational epitope. Thromb Haemost. 1986 Jun 30;55(3):318-24.	
	CHRISTOPHE et al., A monoclonal antibody (B724) to von Willebrand factor recognizing an epitope within the A1 disulphide loop (Cys509-Cys695) discriminates between type 2A and type 2B von Willebrand disease. Br J Haematol. 1995 May;90(1):195-203.	
	CRUZ et al., Mapping the glycoprotein Ib-binding site in the von willebrand factor A1 domain. J Biol Chem. 2000 Jun 23;275(25):19098-105.	
	De Mast et al., Thrombocytopenia and release of activated von willebrand factor during early plasmodium falciparum malaria . J. Inf. Diseases 2007; 196: 622-628	
	D'HAENS et al., Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology. 1999 May;116(5):1029-34.	
	DONG et al., Novel gain-of-function mutations of platelet glycoprotein Ibalpha by valine mutagenesis in the Cys209-Cys248 disulfide loop. Functional analysis under statis and dynamic conditions. J Biol Chem. 2000 Sep 8;275(36):27663-70.	
	DONG et al., Tyrosine sulfation of glycoprotein I(b)alpha. Role of electrostatic interactions in von Willebrand factor binding. J Biol Chem. 2001 May 18;276(20):16690-4. Epub 2001 Feb 23.	
	ELS-CONRATH et al., Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J Biol Chem. 2001 Mar 9;276(10):7346-50. Epub 2000 Oct 25.	
	EMSLEY et al., Crystal structure of the von Willebrand Factor A1 domain and implications for the binding of platelet glycoprotein Ib. J Biol Chem. 1998 Apr 24;273(17):10396-401.	
	FAVALORO et al., Discrimination of von Willebrands disease (VWD) subtypes: direct comparison of von Willebrand factor:collagen binding assay (VWF:CBA) with monoclonal antibody (MAB) based VWF-capture systems. Thromb Haemost. 2000 Oct;84(4):541-7.	
	FAVALORO, Detection of von Willebrand disorder and identification of qualitative von Willebrand factor defects. Direct comparison of commercial ELISA-based von Willebrand factor activity options. Am J Clin Pathol. 2000 Oct;114(4):608-18.	
	FAVALORO et al., Development of a simple collagen based ELISA assay aids in the diagnosis of, and permits sensitive discrimination between type I and type II, von Willebrand's disease. Blood Coagul Fibrinolysis. 1991 Apr;2(2):285-91.	
	FRANCHINI et al., Von Willebrand factor and thrombosis. Ann Hematol. 2006 Jul;85(7):415-23. Epub 2006 Mar 28. Review.	
	FUJIMURA et al., The interaction of botrocetin with normal or variant von Willebrand factor (types IIA and IIB) and its inhibition by monoclonal antibodies that block receptor binding. Thromb Haemost. 1992 Oct 5;68(4):464-9.	
	GENBANK submission; NIH/NCBI; Accession number 1AUQ; Emsley et al; September 1, 1997	

EXAMINER:	/Michael Szperka/	DATE CONSIDERED:	08/31/2009
-----------	-------------------	------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/541,708		ATTY. DOCKET NO.: A0848.70010US00	
				FILING DATE: July 8, 2005		CONFIRMATION NO.: 6032	
				APPLICANT: Karen Silence et al.			
				GROUP ART UNIT: 1644		EXAMINER: Michael Edward Szperka	
Sheet	3	of	4				

		(last submission).	
		GENBANK submission; NIH/NCBI; Accession number 1M10_A; Huizinga et al; September 24, 2008 (last submission).	
		GENBANK submission; NIH/NCBI; Accession number AAA61295; Mancuso et al.; January 14, 1995 (last submission).	
		GENBANK submission; NIH/NCBI; Accession number AAB34053; Clerc et al.; July 27, 1995 (last submission).	
		GENBANK submission; NIH/NCBI; Accession number AAB39987; Schulte am Esch II et al.; January 9, 1997 (last submission).	
		GENBANK submission; NIH/NCBI; Accession number AAB59512; Sadler; August 7, 1995 (last submission).	
		GENBANK submission; NIH/NCBI; Accession number CAA27972; Bonthron et al.; January 9, 1998 (last submission).	
		GENBANK submission; NIH/NCBI; Accession number NP_000164; Forestier et al; January 4, 2009 (last submission).	
		GENBANK submission; NIH/NCBI; Accession number NP_000543; Sun et al; January 4, 2009 (last submission).	
		GENBANK submission; NIH/NCBI; Accession number 1SQ0_A; Dumas et al.; September 24, 2008 (last submission).	
		GOTO et al., Characterization of the unique mechanism mediating the shear-dependent binding of soluble von Willebrand factor to platelets. J Biol Chem. 1995 Oct 6;270(40):23352-61.	
		GROOT et al., The presence of active von Willebrand factor under various pathological conditions. Curr Opin Hematol. 2007 May;14(3):284-9. Review.	
		HUIZINGA et al., Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science. 2002 Aug 16;297(5584):1176-9.	
		IKEDA et al., The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest. 1991 Apr;87(4):1234-40.	
		LATTUADA et al., Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica. 2003 Sep;88(9):1029-34.	
		LÓPEZ et al., Bernard-Soulier syndrome. Blood. 1998 Jun 15;91(12):4397-418. Review.	
		MATSUSHITA et al., Identification of amino acid residues essential for von Willebrand factor binding to platelet glycoprotein Ib. Charged-to-alanine scanning mutagenesis of the A1 domain of human von Willebrand factor. J Biol Chem. 1995 Jun 2;270(22):13406-14.	
		MATSUSHITA et al., Localization of von willebrand factor-binding sites for platelet glycoprotein Ib and botrocetin by charged-to-alanine scanning mutagenesis. J Biol Chem. 2000 Apr 14;275(15):11044-9.	
		MILLER et al., Mutation in the gene encoding the alpha chain of platelet glycoprotein Ib in platelet-type von Willebrand disease. Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4761-5.	
		MURDOCK et al., von Willebrand factor activity detected in a monoclonal antibody-based ELISA: an alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use. Thromb Haemost. 1997 Oct;78(4):1272-7.	
		NERI et al., High-affinity antigen binding by chelating recombinant antibodies (CRAbs). J Mol	

EXAMINER:	DATE CONSIDERED:
/Michael Szperka/	08/31/2009

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/541,708		ATTY. DOCKET NO.: A0848.70010US00		
				FILING DATE: July 8, 2005		CONFIRMATION NO.: 6032		
				APPLICANT: Karen Silence et al.				
				GROUP ART UNIT: 1644		EXAMINER: Michael Edward Szperka		
Sheet	4	of	4					

		Biol. 1995 Feb 24;246(3):367-73.	
		NOKES et al., Von Willebrand factor has more than one binding site for platelets. Thromb Res. 1984 Jun 1;34(5):361-6.	
		RUGGERI, Von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost. 2003 Jul;1(7):1335-42. Review.	
		RUSSELL et al., Pseudo-von Willebrand disease: a mutation in the platelet glycoprotein Ib alpha gene associated with a hyperactive surface receptor. Blood. 1993 Apr 1;81(7):1787-91.	
		SADLER et al., Molecular mechanism and classification of von Willebrand disease. Thromb Haemost. 1995 Jul;74(1):161-6. Review.	
		SADLER, Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67:395-424. Review.	
		SAVAGE et al., Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell. 1996 Jan 26;84(2):289-97.	
		TAIT et al., Phenotype changes resulting in high-affinity binding of von Willebrand factor to recombinant glycoprotein Ib-IX: analysis of the platelet-type von Willebrand disease mutations. Blood. 2001 Sep 15;98(6):1812-8.	
		THOMPSON et al., Advances in the pathogenesis and treatment of acute coronary syndromes. J La State Med Soc. 1999 May;151(5):272-7. Review. Abstract only.	
		TRIPLETT, Coagulation and bleeding disorders: review and update. Clin Chem. 2000 Aug;46(8 Pt 2):1260-9. Review.	
		TSAI et al., Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998 Nov 26;339(22):1585-94.	
		VANHOORELBEKE et al., A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor. Thromb Haemost. 2000 Jan;83(1):107-13.	
		VASUDEVAN et al., Modeling and functional analysis of the interaction between von Willebrand factor A1 domain and glycoprotein Ibalpha. J Biol Chem. 2000 Apr 28;275(17):12763-8.	
		VEYRADIER et al., Laboratory diagnosis of von Willebrand disease. Int J Clin Lab Res. 1998;28(4):201-10. Review.	

[NOTE - No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:
/Michael Szperka/	08/31/2009

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.